Societe Generale’s Jazz Pharmaceuticals JAZZ Stock Holding History

Societe Generale’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$663K	Buy	+4,693	New	+$692K	﹤0.01%	1553

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Societe Generale's JAZZ Position: Q2 2016 in Review

Societe Generale opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2016: 4,693 shares worth $663K. The stake represents ﹤0.01% of the portfolio and ranks #1553 among its holdings.

366 funds tracked by Wall St. Rank hold JAZZ as of Q2 2016.

Societe Generale held 4,693 shares of Jazz Pharmaceuticals worth $663K as of Q2 2016.
Jazz Pharmaceuticals was a new Societe Generale position in Q2 2016.
Jazz Pharmaceuticals made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #1553 holding.
366 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.